<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/ct2/show/NCT02979366</url>
  </required_header>
  <id_info>
    <org_study_id>CL1-64315-001</org_study_id>
    <secondary_id>2016-003768-38</secondary_id>
    <secondary_id>136541</secondary_id>
    <nct_id>NCT02979366</nct_id>
  </id_info>
  <brief_title>Phase I Study of S64315 Administred Intravenously in Patients With Acute Myeloid Leukaemia or Myelodysplastic Syndrome</brief_title>
  <official_title>Phase I, International, Multicentre, Open-label, Non-randomised, Non-comparative Study of Intravenously Administered S64315, a Mcl-1 Inhibitor, in Patients With Acute Myeloid Leukaemia (AML) or Myelodysplastic Syndrome (MDS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut de Recherches Internationales Servier</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>ADIR, a Servier Group company</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Servier</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The CL1-64315-001 study is a phase I, international, multicentre, open-label, non-randomised,&#xD;
      non-comparative study. This study is designed in two parts: one part for dose escalation, one&#xD;
      part for dose expansion.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 15, 2017</start_date>
  <completion_date type="Actual">May 11, 2020</completion_date>
  <primary_completion_date type="Actual">May 11, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of DLTs during the first cycle of treatment with single agent S64315</measure>
    <time_frame>21-day cycle 1</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety tolerance profile of S64315 assessed by:Incidence and severity of AEs</measure>
    <time_frame>From first dose until 30 days after the last dose administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Tolerability: Dose interruptions</measure>
    <time_frame>From first dose until 30 days after the last dose administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Tolerability: Dose reductions</measure>
    <time_frame>From first dose until 30 days after the last dose administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Tolerability: Dose intensity</measure>
    <time_frame>From first dose until 30 days after the last dose administration</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Concentration at the end of infusion (C inf) in plasma</measure>
    <time_frame>D1 and D2 of cycle 1 and 2, D15 and D16 of cycle 1 and D1 from cycle 3 to cycle 6.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative amount of a compound excreted in the urine (Ae)</measure>
    <time_frame>only D1 of cycle 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Preliminary efficacy assessment according to Cheson criteria (adapted for each disease)</measure>
    <time_frame>From first dose until 30 days after the last dose administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time corresponding to end of infusion (tinf/tend) in plasma</measure>
    <time_frame>D1 and D2 of cycle 1 and 2, D15 and D16 of cycle 1 and D1 from cycle 3 to cycle 6.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the concentration-time curve from zero (time of drug administration) to tlast (AUC last) in plasma</measure>
    <time_frame>D1 and D2 of cycle 1 and 2, D15 and D16 of cycle 1 and D1 from cycle 3 to cycle 6.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time corresponding to Clast (tlast) in plasma.</measure>
    <time_frame>D1 and D2 of cycle 1 and 2, D15 and D16 of cycle 1 and D1 from cycle 3 to cycle 6.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Last quantifiable observed concentration (Clast) in plasma</measure>
    <time_frame>D1 and D2 of cycle 1 and 2, D15 and D16 of cycle 1 and D1 from cycle 3 to cycle 6.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve (AUC) in plasma</measure>
    <time_frame>D1 and D2 of cycle 1 and 2, D15 and D16 of cycle 1 and D1 from cycle 3 to cycle 6.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal elimination half-life (t½,z) in plasma</measure>
    <time_frame>D1 and D2 of cycle 1 and 2, D15 and D16 of cycle 1 and D1 from cycle 3 to cycle 6.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>total Clearance (CL)</measure>
    <time_frame>D1 and D2 of cycle 1 and 2, D15 and D16 of cycle 1 and D1 from cycle 3 to cycle 6.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of distribution at steady-state (Vss) in plasma</measure>
    <time_frame>D1 and D2 of cycle 1 and 2, D15 and D16 of cycle 1 and D1 from cycle 3 to cycle 6.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ae expressed as a percentage of the dose (fe) in urine</measure>
    <time_frame>only D1 of cycle 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal clearance (CLR)</measure>
    <time_frame>only D1 of cycle 1</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">38</enrollment>
  <condition>Acute Myeloid Leukaemia (AML)</condition>
  <condition>Myelodysplastic Syndrome (MDS)</condition>
  <arm_group>
    <arm_group_label>S64315 (also referred as MIK665) administered once a week</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>S64315 (also referred as MIK665) administered twice a week</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>S64315 once a week</intervention_name>
    <description>S64315 will be administered via i.v. infusion from 30 minutes and up to 3 hours once every week (21- day cycle), the starting dose is 50 mg. As data emerge during the study, the infusion duration and alternative dosing regimen may be changed.</description>
    <arm_group_label>S64315 (also referred as MIK665) administered once a week</arm_group_label>
    <other_name>MIK665</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>S64315 twice a week</intervention_name>
    <description>S64315 will be administered via i.v. infusion from 30 minutes and up to 3 hours twice every week (28- day cycle), the starting dose is 50 mg. As data emerge during the study, the infusion duration and alternative dosing regimen may be changed.</description>
    <arm_group_label>S64315 (also referred as MIK665) administered twice a week</arm_group_label>
    <other_name>MIK665</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female aged ≥ 18 years;&#xD;
&#xD;
          -  Patients with cytologically confirmed and documented de novo, secondary or&#xD;
             therapy-related AML, excluding acute promyelocytic leukaemia (APL, French-American&#xD;
             British M3 classification):&#xD;
&#xD;
               -  with relapsed or refractory disease without established alternative therapy or&#xD;
&#xD;
               -  secondary to MDS treated at least by hypomethylating agent or&#xD;
&#xD;
               -  &gt; 65 years not previously treated for AML and who are not candidates for&#xD;
                  intensive chemotherapy nor candidates for established alternative chemotherapy Or&#xD;
                  Patients with cytologically confirmed and documented MDS), in relapse or&#xD;
                  refractory after previous treatment line including at least one hypomethylating&#xD;
                  agent and have ≥10% bone marrow blasts;&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status 0 to 2&#xD;
&#xD;
          -  Circulating white blood cells &lt; 10^9 /L (with or without use of hydroxycarbamide).&#xD;
&#xD;
          -  Adequate renal function defined as:&#xD;
&#xD;
             • Serum creatinine ≤ 1.5 x ULN (upper normal limit) or calculated creatinine clearance&#xD;
             (determined by MDRD) &gt; 50 mL/min/1.73m2.&#xD;
&#xD;
          -  LDH &lt; 2 x ULN&#xD;
&#xD;
          -  Adequate hepatic function defined as:&#xD;
&#xD;
               -  AST and ALT ≤ 1.5 x ULN&#xD;
&#xD;
               -  Total bilirubin level ≤ 1.5 x ULN, except for patients with known Gilbert's&#xD;
                  syndrome (confirmed by the UGT1A1 polymorphism analysis), who are excluded if&#xD;
                  total bilirubin&gt;3.0 x ULN or direct bilirubin &gt; 1.5 x ULN&#xD;
&#xD;
          -  Serum CK/CPK ≤2.5 x ULN.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Unlikely to cooperate in the study.&#xD;
&#xD;
          -  Participant already enrolled in the study who has received at least one S64315&#xD;
             infusion.&#xD;
&#xD;
          -  Pregnancy, breastfeeding or possibility of becoming pregnant during the study.&#xD;
&#xD;
          -  Participation in another interventional study requiring investigational treatment&#xD;
             intake within 2 weeks or at least 5 half-lives (whichever is longer) prior to first&#xD;
             dose of S64315 (participation in non-interventional registries or epidemiological&#xD;
             studies is allowed).&#xD;
&#xD;
          -  Presence of ≥ CTCAE grade 2 toxicity (except alopecia of any grade) due to prior&#xD;
             cancer therapy, according to the National Cancer Institute Common Terminology Criteria&#xD;
             for Adverse Events (NCI-CTCAE, version 4.03)&#xD;
&#xD;
          -  Unresolved ≥ CTCAE grade 2 diarrhoea or medical conditions associated with chronic&#xD;
             diarrhoea (such as irritable bowel syndrome, inflammatory bowel disease)&#xD;
&#xD;
          -  Known carriers of HIV antibodies&#xD;
&#xD;
          -  Known history of significant liver disease&#xD;
&#xD;
          -  Uncontrolled hepatitis B or C infection&#xD;
&#xD;
          -  Known active or chronic pancreatitis&#xD;
&#xD;
          -  History of myocardial infarction (MI), angina pectoris, coronary artery bypass graft&#xD;
             (CABG) within 6 months prior to starting study treatment.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrew WEI</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Alfred Hospital, Melbourne, Victoria</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Patient Care Location: Smilow Cancer Hospital at Yale</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06511</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The University of Texas MD Anderson Cancer Center, Department of Leukemia, Division of Cancer Medicine</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Alfred Hospital Department of Haematology</name>
      <address>
        <city>Melbourne</city>
        <zip>3004</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Melbourne Hospital, Department of Clinical Haematology and BMT Service</name>
      <address>
        <city>Melbourne</city>
        <zip>3050</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Paoli-Calmettes Departement d'Hématologie</name>
      <address>
        <city>Marseille</city>
        <zip>13009</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Saint-Antoine Département d'Hematologie Clinique et de Thérapie cellulaire</name>
      <address>
        <city>Paris</city>
        <zip>75012</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Universitaire du Cancer Toulouse Oncopole</name>
      <address>
        <city>Toulouse</city>
        <zip>31059 Cedex9</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Vall d' Hebron/VHIO Hematology Department</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Fe Hematology Department</name>
      <address>
        <city>Valencia</city>
        <zip>46026</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>France</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://clinicaltrials.servier.com/wp-content/uploads/CL1-064315-001-laysummary-2021.02.02.pdf</url>
    <description>Lay Summary</description>
  </link>
  <link>
    <url>https://clinicaltrials.servier.com/wp-content/uploads/CL1-064315-001-anonymisedsynopsis-2020.11.12.pdf</url>
    <description>Results Summary</description>
  </link>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>November 18, 2016</study_first_submitted>
  <study_first_submitted_qc>November 29, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 1, 2016</study_first_posted>
  <last_update_submitted>May 17, 2022</last_update_submitted>
  <last_update_submitted_qc>May 17, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">May 18, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Qualified scientific and medical researchers can request access to anonymized patient-level and study-level clinical trial data.&#xD;
Access can be requested for all interventional clinical studies:&#xD;
used for Marketing Authorization (MA) of medicines and new indications approved after 1 January 2014 in the European Economic Area (EEA) or the United States (US).&#xD;
where Servier is the Marketing Authorization Holder (MAH). The date of the first MA of the new medicine (or the new indication) in one of the EEA Member States will be considered for this scope.&#xD;
In addition, access can be requested for all interventional clinical studies in patients:&#xD;
sponsored by Servier&#xD;
with a first patient enrolled as of 1 January 2004 onwards&#xD;
for New Chemical Entity or New Biological Entity (new pharmaceutical form excluded) for which development has been terminated before any Marketing authorization (MA) approval.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>After Marketing Authorisation in EEA or US if the study is used for the approval.</ipd_time_frame>
    <ipd_access_criteria>Researchers should register on Servier Data Portal and fill in the research proposal form. This form in four parts should be fully documented. The Research Proposal Form will not be reviewed until all mandatory fields are completed.</ipd_access_criteria>
    <ipd_url>https://clinicaltrials.servier.com</ipd_url>
  </patient_data>
  <study_docs>
    <study_doc>
      <doc_type>Individual Participant Data Set</doc_type>
      <doc_url>https://clinicaltrials.servier.com/</doc_url>
    </study_doc>
    <study_doc>
      <doc_type>Study Protocol</doc_type>
      <doc_url>https://clinicaltrials.servier.com/</doc_url>
    </study_doc>
    <study_doc>
      <doc_type>Statistical Analysis Plan</doc_type>
      <doc_url>https://clinicaltrials.servier.com/</doc_url>
    </study_doc>
    <study_doc>
      <doc_type>Informed Consent Form</doc_type>
      <doc_url>https://clinicaltrials.servier.com/</doc_url>
    </study_doc>
    <study_doc>
      <doc_type>Clinical Study Report</doc_type>
      <doc_url>https://clinicaltrials.servier.com/</doc_url>
    </study_doc>
    <study_doc>
      <doc_type>Study-level clinical trial data</doc_type>
      <doc_url>https://clinicaltrials.servier.com/</doc_url>
    </study_doc>
  </study_docs>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>


download date: ClinicalTrials.gov processed this data on September 20, 2023
link text: Link to the current ClinicalTrials.gov record.
url: https://clinicaltrials.gov/ct2/show/NCT02979366
org study id: CL1-64315-001
secondary id: 2016-003768-38
secondary id: 136541
nct id: NCT02979366
lead sponsor: 
collaborator: 
has dmc: No
is fda regulated drug: Yes
is fda regulated device: No
The CL1-64315-001 study is a phase I, international, multicentre, open-label, non-randomised,
      non-comparative study. This study is designed in two parts: one part for dose escalation, one
      part for dose expansion.
allocation: Non-Randomized
intervention model: Single Group Assignment
primary purpose: Treatment
masking: None (Open Label)
measure: Incidence of DLTs during the first cycle of treatment with single agent S64315
time frame: 21-day cycle 1
measure: Safety tolerance profile of S64315 assessed by:Incidence and severity of AEs
time frame: From first dose until 30 days after the last dose administration
measure: Tolerability: Dose interruptions
time frame: From first dose until 30 days after the last dose administration
measure: Tolerability: Dose reductions
time frame: From first dose until 30 days after the last dose administration
measure: Tolerability: Dose intensity
time frame: From first dose until 30 days after the last dose administration
measure: Concentration at the end of infusion (C inf) in plasma
time frame: D1 and D2 of cycle 1 and 2, D15 and D16 of cycle 1 and D1 from cycle 3 to cycle 6.
measure: Cumulative amount of a compound excreted in the urine (Ae)
time frame: only D1 of cycle 1
measure: Preliminary efficacy assessment according to Cheson criteria (adapted for each disease)
time frame: From first dose until 30 days after the last dose administration
measure: Time corresponding to end of infusion (tinf/tend) in plasma
time frame: D1 and D2 of cycle 1 and 2, D15 and D16 of cycle 1 and D1 from cycle 3 to cycle 6.
measure: Area under the concentration-time curve from zero (time of drug administration) to tlast (AUC last) in plasma
time frame: D1 and D2 of cycle 1 and 2, D15 and D16 of cycle 1 and D1 from cycle 3 to cycle 6.
measure: Time corresponding to Clast (tlast) in plasma.
time frame: D1 and D2 of cycle 1 and 2, D15 and D16 of cycle 1 and D1 from cycle 3 to cycle 6.
measure: Last quantifiable observed concentration (Clast) in plasma
time frame: D1 and D2 of cycle 1 and 2, D15 and D16 of cycle 1 and D1 from cycle 3 to cycle 6.
measure: Area Under the Curve (AUC) in plasma
time frame: D1 and D2 of cycle 1 and 2, D15 and D16 of cycle 1 and D1 from cycle 3 to cycle 6.
measure: Terminal elimination half-life (t½,z) in plasma
time frame: D1 and D2 of cycle 1 and 2, D15 and D16 of cycle 1 and D1 from cycle 3 to cycle 6.
measure: total Clearance (CL)
time frame: D1 and D2 of cycle 1 and 2, D15 and D16 of cycle 1 and D1 from cycle 3 to cycle 6.
measure: Volume of distribution at steady-state (Vss) in plasma
time frame: D1 and D2 of cycle 1 and 2, D15 and D16 of cycle 1 and D1 from cycle 3 to cycle 6.
measure: Ae expressed as a percentage of the dose (fe) in urine
time frame: only D1 of cycle 1
measure: Renal clearance (CLR)
time frame: only D1 of cycle 1
arm group label: S64315 (also referred as MIK665) administered once a week
arm group type: Experimental
arm group label: S64315 (also referred as MIK665) administered twice a week
arm group type: Experimental
intervention type: Drug
intervention name: S64315 once a week
description: S64315 will be administered via i.v. infusion from 30 minutes and up to 3 hours once every week (21- day cycle), the starting dose is 50 mg. As data emerge during the study, the infusion duration and alternative dosing regimen may be changed.
arm group label: S64315 (also referred as MIK665) administered once a week
other name: MIK665
intervention type: Drug
intervention name: S64315 twice a week
description: S64315 will be administered via i.v. infusion from 30 minutes and up to 3 hours twice every week (28- day cycle), the starting dose is 50 mg. As data emerge during the study, the infusion duration and alternative dosing regimen may be changed.
arm group label: S64315 (also referred as MIK665) administered twice a week
other name: MIK665
criteria: 
gender: All
minimum age: 18 Years
maximum age: N/A
healthy volunteers: No
last name: Andrew WEI
role: Principal Investigator
affiliation: The Alfred Hospital, Melbourne, Victoria
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
country: Australia
country: France
country: Spain
country: United States
url: https://clinicaltrials.servier.com/wp-content/uploads/CL1-064315-001-laysummary-2021.02.02.pdf
description: Lay Summary
url: https://clinicaltrials.servier.com/wp-content/uploads/CL1-064315-001-anonymisedsynopsis-2020.11.12.pdf
description: Results Summary
responsible party type: Sponsor
mesh term: Leukemia
mesh term: Leukemia, Myeloid
mesh term: Leukemia, Myeloid, Acute
mesh term: Preleukemia
mesh term: Myelodysplastic Syndromes
mesh term: Syndrome
sharing ipd: Yes
ipd description: Qualified scientific and medical researchers can request access to anonymized patient-level and study-level clinical trial data.
Access can be requested for all interventional clinical studies:
used for Marketing Authorization (MA) of medicines and new indications approved after 1 January 2014 in the European Economic Area (EEA) or the United States (US).
where Servier is the Marketing Authorization Holder (MAH). The date of the first MA of the new medicine (or the new indication) in one of the EEA Member States will be considered for this scope.
In addition, access can be requested for all interventional clinical studies in patients:
sponsored by Servier
with a first patient enrolled as of 1 January 2004 onwards
for New Chemical Entity or New Biological Entity (new pharmaceutical form excluded) for which development has been terminated before any Marketing authorization (MA) approval.
ipd info type: Study Protocol
ipd info type: Statistical Analysis Plan (SAP)
ipd info type: Informed Consent Form (ICF)
ipd info type: Clinical Study Report (CSR)
ipd time frame: After Marketing Authorisation in EEA or US if the study is used for the approval.
ipd access criteria: Researchers should register on Servier Data Portal and fill in the research proposal form. This form in four parts should be fully documented. The Research Proposal Form will not be reviewed until all mandatory fields are completed.
ipd url: https://clinicaltrials.servier.com
study doc: 
study doc: 
study doc: 
study doc: 
study doc: 
study doc: 